MUX Insider Carmen Diges Acquires 40,000 Options and 3,900 RSUs
Rhea-AI Filing Summary
McEwen Inc. General Counsel Carmen L. Diges reported acquisitions of equity awards tied to the issuer's common stock. On 08/11/2025 she acquired 40,000 stock options with an exercise price of $10.43 and 3,900 restricted stock units. The option award is subject to a vesting schedule that begins on August 11, 2026 and vests in three equal annual installments. Each restricted stock unit represents a contingent right to one share or cash and vests in three equal installments on December 29, 2025, June 29, 2026 and December 29, 2026.
The reporting form shows these holdings as direct beneficial ownership. The filings identify Ms. Diges as an officer serving as General Counsel and Corporate Secretary and list the number of securities beneficially owned following the transactions as 40,000 options and 3,900 RSUs.
Positive
- Officer alignment: Grants provide direct equity exposure for General Counsel, aligning interests with shareholders
- Clear vesting schedules: Options and RSUs include explicit, multi-date vesting terms
- Direct ownership reported: Holdings are reported as Direct (D), improving transparency
Negative
- None.
Insights
TL;DR: Typical officer equity grant combines time-based options and RSUs to align management with shareholder outcomes.
The grant structure reported is consistent with standard executive compensation: a stock option with a fixed exercise price of $10.43 and a multi-year vesting schedule plus RSUs that convert to shares or cash at the committee's discretion. The option vests in three equal annual installments beginning Aug 11, 2026, which phases potential upside for the officer while retaining long-term retention incentives. The RSU vesting dates are explicit and front-loaded partially in 2025, suggesting near-term retention intent. Impact is routine for governance and compensation monitoring.
TL;DR: Form 4 discloses an officer acquisition of 40,000 options and 3,900 RSUs; disclosures are clear and complete on vesting and conversion terms.
The Form 4 clearly lists the transaction date as 08/11/2025, reports direct beneficial ownership, and provides explicit vesting schedules for both instruments. The RSUs explicitly permit settlement in common stock or cash per the award agreement and vest on specified dates in 2025 and 2026. From a disclosure compliance perspective, the filing contains the required material details for these award grants.